Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis

Subhas C. Ganguli, Chan Guk Park, Martin H. Holtmann, Elizabeth M. Hadac, Terry P. Kenakin, Laurence J Miller

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

G protein-coupled receptors initiate signaling cascades after associating with heterotrimeric G proteins. This is typically initiated by agonist binding, but can also occur spontaneously, particularly in receptors bearing distinct missense mutations. Two such mutations in the parathyroid hormone receptor are associated with constitutive activity, manifesting clinically as Jansen's metaphyseal chondroplasia. We introduce analogous mutations separately and together into the secretin receptor to explore their impact on another family member. Constructs were expressed transiently in COS cells, and had binding and signaling (cAMP generation) studied. Each construct was processed appropriately to lead to cell surface expression and signaling. Secretin bound to the wild-type receptor with two affinity states recognized, 1% of sites in the high affinity state (K(i) = 0.5 ± 0.1 nM) and 99% in the low affinity state (K(i) = 23 ± 3 nM). Mutant receptor binding best fit a single affinity state, having values for K(i) of 5 ± 1 nM (H156R), 8 ± 1 nM (T322P) and 6 ± 1 nM (H156R/T322P), with each of these demonstrating a shift to higher affinity than the predominent low affinity state of the wild-type receptor. Each mutant receptor expressed small to moderate constitutive activity, with basal levels of cAMP activity greater than control (P < .01): H156R, 1.4-fold; T322P, 4.5-fold and H156R/T322P, 6.8-fold. The level of basal activity of even the most active construct was only 15% of the maximal response of wild-type receptor. Although each of the single site mutants responded to secretin by increasing their cAMP levels in a concentration-dependent manner, the dual mutant decreased its cAMP in response to hormone (EC50 = 13 nM). Thus, a natural agonist had become an inverse agonist at this unique construct. Because this could reflect reduced normal coupling with G(s) or increased aberrant coupling with G(i), the mechanism was further explored using pertussis toxin and a stable analogue of GTP. Although ligand-binding determinants were retained in the dual receptor mutant, the conformation of this receptor upon secretin binding effected a reduction in its basal coupling with G(s), thereby resulting in inverse agonism.

Original languageEnglish (US)
Pages (from-to)593-598
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume286
Issue number2
StatePublished - 1998

Fingerprint

Secretin
G-Protein-Coupled Receptors
Mutagenesis
Parathyroid Hormone Receptor Type 1
Heterotrimeric GTP-Binding Proteins
Peptides
Mutation
COS Cells
Pertussis Toxin
Missense Mutation
Guanosine Triphosphate
Hormones
Ligands
secretin receptor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. / Ganguli, Subhas C.; Park, Chan Guk; Holtmann, Martin H.; Hadac, Elizabeth M.; Kenakin, Terry P.; Miller, Laurence J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 286, No. 2, 1998, p. 593-598.

Research output: Contribution to journalArticle

Ganguli, Subhas C. ; Park, Chan Guk ; Holtmann, Martin H. ; Hadac, Elizabeth M. ; Kenakin, Terry P. ; Miller, Laurence J. / Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. In: Journal of Pharmacology and Experimental Therapeutics. 1998 ; Vol. 286, No. 2. pp. 593-598.
@article{2003ecd536234b768c9bdba69d3e1a45,
title = "Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis",
abstract = "G protein-coupled receptors initiate signaling cascades after associating with heterotrimeric G proteins. This is typically initiated by agonist binding, but can also occur spontaneously, particularly in receptors bearing distinct missense mutations. Two such mutations in the parathyroid hormone receptor are associated with constitutive activity, manifesting clinically as Jansen's metaphyseal chondroplasia. We introduce analogous mutations separately and together into the secretin receptor to explore their impact on another family member. Constructs were expressed transiently in COS cells, and had binding and signaling (cAMP generation) studied. Each construct was processed appropriately to lead to cell surface expression and signaling. Secretin bound to the wild-type receptor with two affinity states recognized, 1{\%} of sites in the high affinity state (K(i) = 0.5 ± 0.1 nM) and 99{\%} in the low affinity state (K(i) = 23 ± 3 nM). Mutant receptor binding best fit a single affinity state, having values for K(i) of 5 ± 1 nM (H156R), 8 ± 1 nM (T322P) and 6 ± 1 nM (H156R/T322P), with each of these demonstrating a shift to higher affinity than the predominent low affinity state of the wild-type receptor. Each mutant receptor expressed small to moderate constitutive activity, with basal levels of cAMP activity greater than control (P < .01): H156R, 1.4-fold; T322P, 4.5-fold and H156R/T322P, 6.8-fold. The level of basal activity of even the most active construct was only 15{\%} of the maximal response of wild-type receptor. Although each of the single site mutants responded to secretin by increasing their cAMP levels in a concentration-dependent manner, the dual mutant decreased its cAMP in response to hormone (EC50 = 13 nM). Thus, a natural agonist had become an inverse agonist at this unique construct. Because this could reflect reduced normal coupling with G(s) or increased aberrant coupling with G(i), the mechanism was further explored using pertussis toxin and a stable analogue of GTP. Although ligand-binding determinants were retained in the dual receptor mutant, the conformation of this receptor upon secretin binding effected a reduction in its basal coupling with G(s), thereby resulting in inverse agonism.",
author = "Ganguli, {Subhas C.} and Park, {Chan Guk} and Holtmann, {Martin H.} and Hadac, {Elizabeth M.} and Kenakin, {Terry P.} and Miller, {Laurence J}",
year = "1998",
language = "English (US)",
volume = "286",
pages = "593--598",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis

AU - Ganguli, Subhas C.

AU - Park, Chan Guk

AU - Holtmann, Martin H.

AU - Hadac, Elizabeth M.

AU - Kenakin, Terry P.

AU - Miller, Laurence J

PY - 1998

Y1 - 1998

N2 - G protein-coupled receptors initiate signaling cascades after associating with heterotrimeric G proteins. This is typically initiated by agonist binding, but can also occur spontaneously, particularly in receptors bearing distinct missense mutations. Two such mutations in the parathyroid hormone receptor are associated with constitutive activity, manifesting clinically as Jansen's metaphyseal chondroplasia. We introduce analogous mutations separately and together into the secretin receptor to explore their impact on another family member. Constructs were expressed transiently in COS cells, and had binding and signaling (cAMP generation) studied. Each construct was processed appropriately to lead to cell surface expression and signaling. Secretin bound to the wild-type receptor with two affinity states recognized, 1% of sites in the high affinity state (K(i) = 0.5 ± 0.1 nM) and 99% in the low affinity state (K(i) = 23 ± 3 nM). Mutant receptor binding best fit a single affinity state, having values for K(i) of 5 ± 1 nM (H156R), 8 ± 1 nM (T322P) and 6 ± 1 nM (H156R/T322P), with each of these demonstrating a shift to higher affinity than the predominent low affinity state of the wild-type receptor. Each mutant receptor expressed small to moderate constitutive activity, with basal levels of cAMP activity greater than control (P < .01): H156R, 1.4-fold; T322P, 4.5-fold and H156R/T322P, 6.8-fold. The level of basal activity of even the most active construct was only 15% of the maximal response of wild-type receptor. Although each of the single site mutants responded to secretin by increasing their cAMP levels in a concentration-dependent manner, the dual mutant decreased its cAMP in response to hormone (EC50 = 13 nM). Thus, a natural agonist had become an inverse agonist at this unique construct. Because this could reflect reduced normal coupling with G(s) or increased aberrant coupling with G(i), the mechanism was further explored using pertussis toxin and a stable analogue of GTP. Although ligand-binding determinants were retained in the dual receptor mutant, the conformation of this receptor upon secretin binding effected a reduction in its basal coupling with G(s), thereby resulting in inverse agonism.

AB - G protein-coupled receptors initiate signaling cascades after associating with heterotrimeric G proteins. This is typically initiated by agonist binding, but can also occur spontaneously, particularly in receptors bearing distinct missense mutations. Two such mutations in the parathyroid hormone receptor are associated with constitutive activity, manifesting clinically as Jansen's metaphyseal chondroplasia. We introduce analogous mutations separately and together into the secretin receptor to explore their impact on another family member. Constructs were expressed transiently in COS cells, and had binding and signaling (cAMP generation) studied. Each construct was processed appropriately to lead to cell surface expression and signaling. Secretin bound to the wild-type receptor with two affinity states recognized, 1% of sites in the high affinity state (K(i) = 0.5 ± 0.1 nM) and 99% in the low affinity state (K(i) = 23 ± 3 nM). Mutant receptor binding best fit a single affinity state, having values for K(i) of 5 ± 1 nM (H156R), 8 ± 1 nM (T322P) and 6 ± 1 nM (H156R/T322P), with each of these demonstrating a shift to higher affinity than the predominent low affinity state of the wild-type receptor. Each mutant receptor expressed small to moderate constitutive activity, with basal levels of cAMP activity greater than control (P < .01): H156R, 1.4-fold; T322P, 4.5-fold and H156R/T322P, 6.8-fold. The level of basal activity of even the most active construct was only 15% of the maximal response of wild-type receptor. Although each of the single site mutants responded to secretin by increasing their cAMP levels in a concentration-dependent manner, the dual mutant decreased its cAMP in response to hormone (EC50 = 13 nM). Thus, a natural agonist had become an inverse agonist at this unique construct. Because this could reflect reduced normal coupling with G(s) or increased aberrant coupling with G(i), the mechanism was further explored using pertussis toxin and a stable analogue of GTP. Although ligand-binding determinants were retained in the dual receptor mutant, the conformation of this receptor upon secretin binding effected a reduction in its basal coupling with G(s), thereby resulting in inverse agonism.

UR - http://www.scopus.com/inward/record.url?scp=0032410647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032410647&partnerID=8YFLogxK

M3 - Article

C2 - 9694908

AN - SCOPUS:0032410647

VL - 286

SP - 593

EP - 598

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -